Mesothelioma Law Firm

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma Reviewed by Unknown on November 13, 2020 Rating: 5

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy Reviewed by Unknown on November 12, 2020 Rating: 5

Complications and Predictive Factors for Air Leak > 10 Days with Neoadjuvant Chemotherapy Followed by Pleurectomy/Decortication for Malignant Pleural Mesothelioma Reviewed by Unknown on November 11, 2020 Rating: 5

Mesothelioma risk among those exposed to chrysotile asbestos only and mixtures that include amphibole: a case-control study in the USA, 1975-1980 Reviewed by Unknown on November 10, 2020 Rating: 5

The influence of genetic variability in IL1B and MIR146A on the risk of pleural plaques and malignant mesothelioma Reviewed by Unknown on November 09, 2020 Rating: 5

The influence of genetic variability in IL1B and MIR146A on the risk of pleural plaques and malignant mesothelioma Reviewed by Unknown on November 09, 2020 Rating: 5

CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative Reviewed by Unknown on November 06, 2020 Rating: 5

A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma Reviewed by Unknown on November 05, 2020 Rating: 5

Effect of asbestos exposure on differentiation and function of cytotoxic T lymphocytes Reviewed by Unknown on November 04, 2020 Rating: 5

Locoregional control and toxicity after pleurectomy/decortication and intensity-modulated pleural radiation therapy in patients with malignant pleural mesothelioma Reviewed by Unknown on November 03, 2020 Rating: 5

Identification of Potential Hub Genes and Therapeutic Drugs in Malignant Pleural Mesothelioma by Integrated Bioinformatics Analysis Reviewed by Unknown on November 02, 2020 Rating: 5

Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma Reviewed by Unknown on October 30, 2020 Rating: 5

The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma Reviewed by Unknown on October 29, 2020 Rating: 5

Immunotherapy for mesothelioma: rationale and new approaches Reviewed by Unknown on October 28, 2020 Rating: 5

Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy Reviewed by Unknown on October 27, 2020 Rating: 5

Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis Reviewed by Unknown on October 26, 2020 Rating: 5

AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression Reviewed by Unknown on October 16, 2020 Rating: 5

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Reviewed by Unknown on October 15, 2020 Rating: 5

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study Reviewed by Unknown on October 09, 2020 Rating: 5

Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report) Reviewed by Unknown on October 08, 2020 Rating: 5